Professor Hirohide Saito at the Dept of Reprogramming Science is a bioengineer who makes tools for iPSC researchers. His latest technology, the microRNA (miRNA) switch, is designed to detect and sort live cells not by surface receptors, but by miRNAs. miRNA is a better marker of cell types and can therefore improve purity levels. His miRNA switches consist of synthetic mRNA sequences that include a recognition sequence for miRNA and an open reading frame (ORF) that codes a desired gene, such as a regulatory protein that emits fluorescence or promotes cell death. If the miRNA recognition sequence binds to miRNA expressed in the desired cells, the expression of the regulatory protein is suppressed, thus distinguishing the cell type from others that do not contain the miRNA and express the protein.
Senior Lecturer Yoshinori Yoshida is a cardiomyocyte specialist also at the Dept of Reprogramming Science who immediately saw the potential of this technology. He has been studying how iPS cells can be used to combat cardiac diseases, but has been stymied by unsatisfactory purity levels. Cardiomyocytes are especially difficult to purify because they do not express unique surface receptors. The two scientists therefore collaborated to investigate the effectiveness of miRNA switches for these cells.
By applying the miRNA switches to a defined cardiomyocyte cell line, they were able to identify miRNAs unique to cardiomyocytes. From there, miRNA switches that contained sequences complementary to these miRNAs were constructed. The result was far better purification than that achieved by standard methods. Furthermore, because this technology is RNA-based, it does not integrate into the genome, which makes the cells eligible for clinical application.
Yoshida sees this tool as remarkably simple and something that can be used by stem cell researchers studying any organ. "It is just synthesizing RNA and transfecting them. It is not difficult," he said. To prove this point, he and Saito applied their miRNA switches to the purification of hepatocytes and pancreatic cells, neither of which has unique cell surface markers, finding miRNA switches effective there too.
Intriguingly, the performance of different miRNA switches varied with cell development, suggesting that strategic selection of miRNAs could separate cardiomyocytes at different developmental stages and lead to an even more homogeneous cell pool and potentially better cell therapy outcomes.
Saito believes that with further development, miRNA switches will be applicable to all cell types at all cell stages. "We want to make an active miRNA dictionary for each cell type, so that if we want to isolate this kind of cell type, we know how to use this kind of switch," he said.
The research paper was published online in Cell Stem Cell on May 21 EST.